Literature DB >> 6831454

Alteration of immunogenicity of xenogenized tumor cells in syngeneic rats by the immune responses to virus-associated antigens produced on immunizing cells.

M Hosokawa, T Okayasu, K Ikeda, H Katoh, Y Suzuki, H Kobayashi.   

Abstract

A strong transplantation resistance to a fibrosarcoma (KMT-17) is induced in syngeneic Wistar King Aptekman/Hok rats after a single s.c. immunization with Friend virus-infected (xenogenized) viable KMT-17 cells. The resistance induced by the repeated immunizations with irradiated Friend virus-infected KMT-17 cells, however, was unexpectedly weaker when compared with that induced by irradiated KMT-17 cells. The immunogenicity of tumor-associated antigen on xenogenized Friend virus-infected KMT-17 cells was correlated with their shortened survival time in the peritoneal cavity after i.p. inoculation, especially in rats preimmunized with xenogenized tumor cells. Furthermore, xenogenized tumor cells producing a medium amount of virus-associated antigen (VAA) but not those producing a large amont of VAA showed an augmented immunogenicity even in normal rats. On the other hand, the tumor-associated antigen immunogenicity was augmented by immunization with xenogenized tumor cells which expressed a relatively small amount of VAA in rats presensitized with VAA. These findings indicate that the immunogenicity of xenogenized tumor cells is augmented by the middle-grade immune responses to VAA produced on xenogenized tumor cells.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6831454

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  10 in total

1.  Immunogenicity of viable tumor cells. A comparison of xenogenized tumor cells and BCG-tumor cell mixtures.

Authors:  Y Suzuki; K Suzuki; M Hosokawa; H Kobayashi
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

2.  Regression mechanisms of mouse fibrosarcoma cells after in vitro exposure to quercetin: diminution of tumorigenicity with a corresponding decrease in the production of prostaglandin E2.

Authors:  F Okada; M Hosokawa; J Hasegawa; M Ishikawa; I Chiba; Y Nakamura; H Kobayashi
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

3.  The improved effects of specific active immunotherapy on a rat fibrosarcoma by antitumor drugs.

Authors:  M Komatsumoto; M Hosokawa; F Okada; T Okayasu; T Tanabe; H Kobayashi
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

4.  Immunotherapy of tumor-bearing mice utilizing virus help.

Authors:  Y Shimizu; K Hasumi; K Masubuchi; Y Okudaira
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

5.  Retention of immunogenicity after X-irradiation of mouse colon tumor cells expressing the transfected influenza virus hemagglutinin gene.

Authors:  T Itaya; B Hunt; P Frost
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

6.  The augmentation of tumor-specific immunity by virus help. III. Enhanced generation of tumor-specific Lyt-1+2- T cells is responsible for augmented tumor immunity in vivo.

Authors:  T Yoshioka; M Fukuzawa; Y Takai; N Wakamiya; S Ueda; S Kato; H Fujiwara; T Hamaoka
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

7.  Feasibility of UV-inactivated vaccinia virus in the modification of tumor cells for augmentation of their immunogenicity.

Authors:  N Wakamiya; Y L Wang; H Imai; H X Gu; S Ueda; S Kato
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

8.  Treatment of experimental tumors with a combination of a pulsing magnetic field and an antitumor drug.

Authors:  Y Omote; M Hosokawa; M Komatsumoto; T Namieno; S Nakajima; Y Kubo; H Kobayashi
Journal:  Jpn J Cancer Res       Date:  1990-09

9.  Xenogenization of tumor cells by transfection with plasmid containing env gene of Friend leukemia virus.

Authors:  C Sugiura; T Itaya; N Kondoh; T Oikawa; N Kuzumaki; N Takeichi; M Hosokawa; H Kobayashi
Journal:  Jpn J Cancer Res       Date:  1988-12

10.  Tumor cells treated with vaccinia virus can activate the alternative pathway of mouse complement.

Authors:  N Wakamiya; N Okada; Y L Wang; T Ito; S Ueda; S Kato; H Okada
Journal:  Jpn J Cancer Res       Date:  1989-08
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.